Effect of add-on Doxofylline on Lung Function in Stable COPD

Summary

It is a phase IV, prospective, interventional, single blind, randomized, crossover trial in which the investigators will evaluate the effects of a 4-week treatment with doxofylline 400 mg bid, in add-on to maximal inhalation therapy, in clinically stable COPD patients.

Timeline

Start

2026-12-01

Primary completion

2027-12-01

Completion

2027-12-30

Drugs

Indications